Key Developments Driving the Biotech Industry

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts the life sciences trends across recent genetic technology and biopharma advances. Genetic technology, biopharmaceuticals development and regulatory approval, CRISPR/Cas9 gene editing technology, and CAR-T cell therapy are profiled in the TOE. The corresponding clinical trials scenario for genetically modified T-cell immunotherapy for the treatment of cancer is also presented.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic

Table of Contents

Key Developments Driving the Biotech IndustryRecent Genetic Technology and Biopharma AdvancesLeveraging CRISPR/Cas9 Editing for CAR-T TherapiesLandmark Regulatory Approval for Comprehensive Genomic Profiling AssayExosome Therapeutics Technology Raises $76.5 Million in Series C Funding$114 Million Raised in Series B Financing for Diabetes TherapyClinical Trial Advances and Industry InteractionsRecent Advances in CAR-T TherapiesSummary of Key Contacts

Related Research

Release Date : 21-Nov-18

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.